



AN 2003:551516 CAPLUS
 DN 139:117268
 TI Preparation of deazapurines for use in pharmaceutical compositions for the treatment of inflammatory, autoimmune and proliferative diseases
 IN Daun, Jane; Davis, Heather A.; Gusovsky, Fabian; Hishinuma, Ieharu; Jiang, Yimin; Kaneko, Toshihiko; Kikuchi, Kouichi; Kobayashi, Seiichi; Lescarbeau, Andre; Li, Xiang-Li; Muramoto, Kenzo; Ohi, Norihito; Pesant, Marc; Seletsky, Boris M.; Soejima, Motohiko; Yao, Ye; Yokohama, Hiromitsu; Zhao, Janet Y.; Zheng, Wanjun; Tremblay, Lynda
 PA Eisai Co. Ltd., Japan
 SO PCT Int. Appl., 215 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003057696	A1	20030717	WO 2003-US366	20030107
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2002-346598P	P	20020107		
OS	MARPAT 139:117268				
GI					



AB Indolyldeazapurines, such as I [R1 = H, NH2, alkylamino, acylamino, etc.; R2 = H, amino, alkoxy, alkyl, etc.; R3 = H, CN, halogen, heteroaryl, amino, carbamoyl, etc.], were prepd. for therapeutic use as inhibitors of cell adhesion, mol. expression and inflammatory cytokine signal transduction. These deazapurines are useful in the treatment of inflammatory, autoimmune, proliferative, central nervous system and cardiovascular diseases, such as rheumatoid arthritis, ulcerative colitis, multiple sclerosis, asthma, psoriasis, allograft rejection/graft vs. host disease, idiopathic thrombocytopenia, allergic rhinitis, atopic dermatitis, systemic lupus, glomerulonephritis, diabetes, ulcerative colitis/Crohn's disease, erythematous, eczema, urticaria, myasthenia gravis, idiopathic thrombocytopenia purpura and cancer. Thus, deazapurine II was prepd. via a coupling reaction of the corresponding halodeazapurine

with 2-(tributylstannyl)-1H-indole-1-carboxylic acid 1,1-dimethylethyl ester. The prepd. deazapurines were assayed for cellular cytokine inhibition using human umbilical vein endothelial cells (HUVEC).


IT 562082-85-3P, ER 806843 562082-88-6P, ER 806901

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of indolyldeazapurines for use in pharmaceutical compns. for the treatment of inflammatory, autoimmune and proliferative diseases)


RN 562082-85-3 CAPLUS

CN Methanone, 1-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-6-yl]methyl]-4-piperidinyl(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 562082-88-6 CAPLUS

CN Piperidine, 1-[[2-(5-amino-2-methyl-1H-imidazo[4,5-b]pyridin-7-yl)-1H-indol-6-yl]carbonyl]-4-(4-fluorobenzoyl)- (9CI) (CA INDEX NAME)




RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

AN 1999:295926 CAPLUS
 DN 131:67650
 TI Design and synthesis of potent and selective 5,6-fused heterocyclic
 thrombin inhibitors
 AU Dominguez, Celia; Duffy, Daniel E.; Han, Qi; Alexander, Richard S.;
 Galemme, Robert A., Jr.; Park, Jeongsook M.; Wong, Pancras C.; Amparo,
 Eugene C.; Knabb, Robert M.; Luetttgen, Joseph; Wexler, Ruth R.
 CS DuPont Pharmaceuticals Company, Wilmington, DE, 19880-0500, USA
 SO Bioorganic & Medicinal Chemistry Letters (1999), 9(7), 925-930
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier Science Ltd.
 DT Journal
 LA English
 AB Thrombin, a serine protease, plays a central role in the initiation of
 thrombotic events. We report the design, synthesis, and antithrombotic
 efficacy of XU817 (7), a nonpeptide 5-(amidino)indole thrombin inhibitor.
 Utilizing the co-crystal structure of XU817 bound in the active site of
 thrombin we were able to synthesize analogs with enhanced thrombin
 affinity.
 IT **228552-27-0P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (design and synthesis of potent and selective 5,6-fused heterocyclic
 thrombin inhibitors)
 RN 228552-27-0 CAPLUS
 CN Piperidine, 1-(1H-indol-6-ylsulfonyl)-4-(phenylmethyl)- (9CI) (CA INDEX
 NAME)




IT **228552-28-1P**
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological
 study); PREP (Preparation); USES (Uses)
 (design and synthesis of potent and selective 5,6-fused heterocyclic
 thrombin inhibitors)
 RN 228552-28-1 CAPLUS
 CN 1H-Indole-3-carboximidamide, 6-[[4-(phenylmethyl)-1-piperidinyl]sulfonyl]-
 (9CI) (CA INDEX NAME)




RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

AN 1999:295926 CAPLUS
 DN 131:67650
 TI Design and synthesis of potent and selective 5,6-fused heterocyclic
 thrombin inhibitors
 AU Dominguez, Celia; Duffy, Daniel E.; Han, Qi; Alexander, Richard S.;
 Galemme, Robert A., Jr.; Park, Jeongsook M.; Wong, Pancras C.; Amparo,
 Eugene C.; Knabb, Robert M.; Luetttgen, Joseph; Wexler, Ruth R.
 CS DuPont Pharmaceuticals Company, Wilmington, DE, 19880-0500, USA
 SO Bioorganic & Medicinal Chemistry Letters (1999), 9(7), 925-930
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier Science Ltd.
 DT Journal
 LA English
 AB Thrombin, a serine protease, plays a central role in the initiation of
 thrombotic events. We report the design, synthesis, and antithrombotic
 efficacy of XU817 (7), a nonpeptide 5-(amidino)indole thrombin inhibitor.
 Utilizing the co-crystal structure of XU817 bound in the active site of
 thrombin we were able to synthesize analogs with enhanced thrombin
 affinity.
 IT **228552-27-0P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (design and synthesis of potent and selective 5,6-fused heterocyclic
 thrombin inhibitors)
 RN 228552-27-0 CAPLUS
 CN Piperidine, 1-(1H-indol-6-ylsulfonyl)-4-(phenylmethyl)- (9CI) (CA INDEX
 NAME)




AN 1999:295926 CAPLUS
 DN 131:67650
 TI Design and synthesis of potent and selective 5,6-fused heterocyclic thrombin inhibitors
 AU Dominguez, Celia; Duffy, Daniel E.; Han, Qi; Alexander, Richard S.; Galemno, Robert A., Jr.; Park, Jeongsook M.; Wong, Pancras C.; Amparo, Eugene C.; Knabb, Robert M.; Luetttgen, Joseph; Wexler, Ruth R.
 CS DuPont Pharmaceuticals Company, Wilmington, DE, 19880-0500, USA
 SO Bioorganic & Medicinal Chemistry Letters (1999), 9(7), 925-930
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier Science Ltd.
 DT Journal
 LA English
 AB Thrombin, a serine protease, plays a central role in the initiation of thrombotic events. We report the design, synthesis, and antithrombotic efficacy of XU817 (7), a nonpeptide 5-(amidino)indole thrombin inhibitor. Utilizing the co-crystal structure of XU817 bound in the active site of thrombin we were able to synthesize analogs with enhanced thrombin affinity.
 IT **228552-28-1P**
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (design and synthesis of potent and selective 5,6-fused heterocyclic thrombin inhibitors)
 RN 228552-28-1 CAPLUS
 CN 1H-Indole-3-carboximidamide, 6-[[4-(phenylmethyl)-1-piperidinyl]sulfonyl]-(9CI) (CA INDEX NAME)



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

AN 2001:762850 CAPLUS
 DN **135:313624**
 TI Soluble .beta.-amyloid precursor protein secretion promoters and preparation thereof
 IN Kakihana, Mitsuru; Kato, Kaneyoshi; Mori, Masaaki; Yamashita, Toshiro
 PA Takeda Chemical Industries, Ltd., Japan
 SO PCT Int. Appl., 156 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001076629	A1	20011018	WO 2001-JP2961	20010405
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG EP 1283055 A1 20030212 EP 2001-919795 20010405 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR JP 2001348332 A2 20011218 JP 2001-108395 20010406 PRAI JP 2000-111912 A 20000407 WO 2001-JP2961 W 20010405 OS MARPAT 135:313624 GI				




AB Disclosed are compds. represented by the following general formula I, salts thereof or prodrugs thereof, use of the same, and a process for producing the same wherein R1, R2 = H, lower alkyl, etc.; the ring A represents an optionally substituted benzene ring; X = O, etc.; and Y represents CH or N. Because of having a potent effect of promoting the secretion of sol. .beta.-amyloid precursor proteins (sAPP), these compds. and the like inhibit functional disorders and apoptosis of cells (in particular, nerve cells) mediated by the thus secreted sol. .beta.-amyloid precursor proteins having a neurotrophic factor-like effect. A compd. cis-(4-anilino-2-methyl-3,4-dihydro-1(2H)-quinoliny1)(2-fury1)methane was prepd., and its promotion effect on sAPP secretion and inhibitory effect on apoptosis in PC12h cells were examd.

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2003 ACS on STN
 RN **367510-05-2** REGISTRY
 CN 4-Quinolinamine, 1-(1,3-benzodioxol-5-ylcarbonyl)-1,2,3,4-tetrahydro-2-methyl-N-phenyl-, (2R,4R)-rel- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C24 H22 N2 O3
 SR CA
 LC STN Files: CA, CAPLUS

Relative stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2003 ACS on STN
 RN **367508-34-7** REGISTRY
 CN 4-Quinolinamine, 1-(1,3-benzodioxol-5-ylcarbonyl)-1,2,3,4-tetrahydro-2-methyl-N-phenyl-, (2R,4S)-rel- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C24 H22 N2 O3
 SR CA
 LC STN Files: CA, CAPLUS

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)

=> d 2002:1367700

ANSWER 1 CHEMCATS COPYRIGHT 2003 ACS on STN

Accession No. (AN): 2002:1367700 CHEMCATS

Catalog Name (CO): ChemBridge Product List

Publication Date (PD): 17 Jan 2002

Order Number (ON): 5270081

Chemical Name (CN): 9H-Carbazole, 9-ethyl-3-[[4-(phenylmethyl)-1-piperidinyl]methyl]-

CAS Registry No. (RN): 414893-18-8

Supplementary Term (ST): CHEMICAL LIBRARY

Structure :

